CLINICAL_TRIALS trial_result · 2021-04-12

Clinical Trial Update: Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia [Phase 2]

This completed Phase 2 trial evaluated the safety, pharmacokinetics, and efficacy of MP-214 in adults with schizophrenia. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Tanabe Pharma Corporation | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2021-04-12